Höftberger R, Lassmann H. Inflammatory demyelinating diseases of the central nervous system. Handb Clin Neurol. 2018; 145:263–83.

Akay LA, Effenberger AH, Tsai L-H. Cell of all trades: oligodendrocyte precursor cells in synaptic, vascular, and immune function. Genes Dev. 2021;35:180–98.

Chang A, Nishiyama A, Peterson J, Prineas J, Trapp BD. NG2-positive oligodendrocyte progenitor cells in adult human brain and multiple sclerosis lesions. J Neurosci. 2000;20(17):6404–12.

Hughes EG, Kang SH, Fukaya M, Bergles DE. Oligodendrocyte progenitors balance growth with self-repulsion to achieve homeostasis in the adult brain. Nat Neurosci. 2013;16(6):668–76.

Gruchot J, Weyers V, Göttle P, Förster M, Hartung H-P, Küry P, et al. The molecular basis for remyelination failure in multiple sclerosis. Cells. 2019;8:825. Available from: https://www.mdpi.com/2073-4409/8/8/825.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Franklin RJM, Ffrench-Constant C. Remyelination in the CNS: From biology to therapy. Nat Rev Neurosci. 2008;9(11):839–55.

Dawson MRL, Polito A, Levine JM, Reynolds R. NG2-expressing glial progenitor cells: an abundant and widespread population of cycling cells in the adult rat CNS. Mol Cell Neurosci. 2003;24:476–88.

Article  CAS  PubMed  Google Scholar 

Raft MC, Miller RH, Noble M. A glial progenitor cell that develops in vitro into an astrocyte or an oligodendrocyte depending on culture medium. Nature. 1983;303(5916):390–6.

Nait-Oumesmar B, Decker L, Lachapelle F, Avellana-Adalid V, Bachelin C, Baron-Van Evercooren A. Progenitor cells of the adult mouse subventricular zone proliferate, migrate and differentiate into oligodendrocytes after demyelination. Eur J Neurosci. 1999;11:4357–66.

Moyon S, Dubessy AL, Aigrot MS, Trotter M, Huang JK, Dauphinot L, et al. Demyelination causes adult CNS progenitors to revert to an immature state and express immune cues that support their migration. J Neurosci. 2015;35(1):4–20.

Boyd A, Zhang H, Williams A. Insufficient OPC migration into demyelinated lesions is a cause of poor remyelination in MS and mouse models. Acta Neuropathol. 2013;125:841–59.

Talbott JF, Loy DN, Liu Y, Qiu MS, Bunge MB, Rao MS, et al. Endogenous Nkx2.2+/Olig2+ oligodendrocyte precursor cells fail to remyelinate the demyelinated adult rat spinal cord in the absence of astrocytes. Exp Neurol. 2005;192(1):11–24.

Watanabe M, Hadzic T, Nishiyama A. Transient upregulation of Nkx2.2 expression in oligodendrocyte lineage cells during remyelination. Glia. 2004;46(3):311–22.

Fancy SPJ, Zhao C, Franklin RJM. Increased expression of Nkx2.2 and Olig2 identifies reactive oligodendrocyte progenitor cells responding to demyelination in the adult CNS. Mol Cell Neurosci. 2004;27(3):247–54.

Vana AC, Lucchinetti CF, Le TQ, Armstrong RC. Myelin transcription factor 1 (Myt1) expression in demyelinated lesions of rodent and human CNS. Glia. 2007;55(7):687–97.

Heß K, Starost L, Kieran NW, Thomas C, Vincenten MCJ, Antel J, et al. Lesion stage-dependent causes for impaired remyelination in MS. Acta Neuropathol. 2020;140:359–75.

Wolswijk G. Oligodendrocyte survival, loss and birth in lesions of chronic-stage multiple sclerosis. Brain. 2000;123(1):105–15.

Wegener A, Deboux C, Bachelin C, Frah M, Kerninon C, Seilhean D, et al. Gain of Olig2 function in oligodendrocyte progenitors promotes remyelination. Brain. 2015;138(1):120–35.

Lin K, Bieri G, Gontier G, Müller S, Smith LK, Snethlage CE, et al. MHC class I H2-Kb negatively regulates neural progenitor cell proliferation by inhibiting FGFR signaling. PLoS Biol. 2021; 19(6):e3001311.

Wolswijk G. Chronic stage multiple sclerosis lesions contain a relatively quiescent population of oligodendrocyte precursor cells. J Neurosci. 1998;18(2):601–9.

Faissner S, Plemel JR, Gold R, Yong VW. Progressive multiple sclerosis: from pathophysiology to therapeutic strategies. Nat Rev Drug Discov. 2019;18(12):905–22.

Franklin RJM. Why does remyelination fail in multiple sclerosis? Nat Rev Neurosci. 2002;3(9):705–14.

Lassmann H, Brück W, Lucchinetti C, Rodriguez M. Remyelination in multiple sclerosis. Mult Scler. 1997;3(2):133–6.

Lubetzki C, Zalc B, Williams A, Stadelmann C, Stankoff B. Remyelination in multiple sclerosis: from basic science to clinical translation. Lancet Neurol [Internet]. 2020;19:678–88. Available from: https://doi.org/10.1016/S1474-4422(20)30140-X

Kuhlmann T, Miron V, Cuo Q, Wegner C, Antel J, Brück W. Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis. Brain. 2008;131(7):1749–58.

Tepavčević V, Lubetzki C. Oligodendrocyte progenitor cell recruitment and remyelination in multiple sclerosis: the more, the merrier? Brain. 2022;145:4178–92.

Article  PubMed  Google Scholar 

Ciotti JR, Cross AH. Disease-Modifying Treatment in Progressive Multiple Sclerosis. Curr Treat Options Neurol. 2018;20:1–26.

Green AJ, Gelfand JM, Cree BA, Bevan C, Boscardin WJ, Mei F, et al. Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial. Lancet. 2017;390(10111):2481–9.

Cree BAC, Hartung H-P, Barnett M. New drugs for multiple sclerosis: new treatment algorithms. Curr Opin Neurol. 2022;35:262–70.

Article  PubMed  Google Scholar 

Franklin RJM, Ffrench-Constant C. Regenerating CNS myelin - From mechanisms to experimental medicines. Nat Rev Neurosci. 2017;18(12):753–69.

Najm FJ, Madhavan M, Zaremba A, Shick E, Karl RT, Factor DC, et al. Drug-based modulation of endogenous stem cells promotes functional remyelination in vivo. Nature. 2015;522:216–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Du C, Duan Y, Wei W, Cai Y, Chai H, Lv J, et al. Kappa opioid receptor activation alleviates experimental autoimmune encephalomyelitis and promotes oligodendrocyte-mediated remyelination. Nat Commun. 2016;7:11120.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Deshmukh VA, Tardif V, Lyssiotis CA, Green CC, Kerman B, Kim HJ, et al. A regenerative approach to the treatment of multiple sclerosis. Nature. 2013;502:327–32.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Suo N, Guo Y e., He B, Gu H, Xie X. Inhibition of MAPK/ERK pathway promotes oligodendrocytes generation and recovery of demyelinating diseases. Glia. 2019;67(7):1320–32.

Wang PS, Wang J, Xiao ZC, Pallen CJ. Protein-tyrosine phosphatase α acts as an upstream regulator of Fyn signaling to promote oligodendrocyte differentiation and myelination. J Biol Chem. 2009;284(48):33692–702.

Baron W, De Jonge JC, De Vries H, Hoekstra D. Regulation of oligodendrocyte differentiation: Protein kinase C activation prevents differentiation of O2A progenitor cells toward oligodendrocytes. Glia. 1998;22(2):121–9.

Pedraza CE, Taylor C, Pereira A, Seng M, Tham CS, Izrael M, et al. Induction of oligodendrocyte differentiation and in vitro myelination by inhibition of Rho-associated kinase. ASN Neuro. 2014;6(4):1759091414538134.

Baer AS, Syed YA, Kang SU, Mitteregger D, Vig R, Ffrench-Constant C, et al. Myelin-mediated inhibition of oligodendrocyte precursor differentiation can be overcome by pharmacological modulation of Fyn-RhoA and protein kinase C signalling. Brain. 2009;

Huang JK, Jarjour AA, Nait Oumesmar B, Kerninon C, Williams A, Krezel W, et al. Retinoid X receptor gamma signaling accelerates CNS remyelination. Nat Neurosci. 2011;14:45–53.

Article  CAS  PubMed  Google Scholar 

Manousi A, Küry P. Small molecule screening as an approach to encounter inefficient myelin repair. Curr Opin Pharmacol. 2021;61:127–35.

Kopanitsa M V., Lehtimäki KK, Forsman M, Suhonen A, Koponen J, Piiponniemi TO, et al. Cognitive disturbances in the cuprizone model of multiple sclerosis. Genes Brain Behav. 2021;20(1):e12663.

Sams EC. Oligodendrocytes in the aging brain. Neuronal Signal. 2021;5(3):NS20210008.

Tiane A, Schepers M, Riemens R, Rombaut B, Vandormael P, Somers V, et al. DNA methylation regulates the expression of the negative transcriptional regulators ID2 and ID4 during OPC differentiation. Cell Mol Life Sci. 2021;78:6631–44.

Neumann B, Baror R, Zhao C, Segel M, Dietmann S, Rawji KS, et al. Metformin Restores CNS Remyelination Capacity by Rejuvenating Aged Stem Cells. Cell Stem Cell. 2019;25(4):473–85.e8.

de Faria O, Dhaunchak AS, Kamen Y, Roth AD, Kuhlmann T, Colman DR, et al. TMEM10 promotes oligodendrocyte differentiation and is expressed by oligodendrocytes in human remyelinating multiple sclerosis plaques. Sci Rep. 2019;9(1):3606.

Duncan GJ, Plemel JR, Assinck P, Manesh SB, Muir FGW, Hirata R, et al. Myelin regulatory factor drives remyelination in multiple sclerosis. Acta Neuropathol. 2017;134(3):403–22.

Tran JQ, Rana J, Barkhof F, Melamed I, Gevorkyan H, Wattjes MP, et al. Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033. Neurol Neuroimmunol Neuroinflamm. 2014;1(2):e18.

Fan H, Zhao JG, Yan JQ, Du GQ, Fu QZ, Shi J, et al. Effect of Notch1 gene on remyelination in multiple sclerosis in mouse models of acute demyelination. J Cell Biochem. 2018;119(11):9284–94.

Berghoff SA, Spieth L, Sun T, Hosang L, Depp C, Sasmita AO, et al. Neuronal cholesterol synthesis is essential for repair of chronically demyelinated lesions in mice. Cell Rep. 2021;37(4):109889.

Saher G, Brügger B, Lappe-Siefke C, Möbius W, Tozawa RI, Wehr MC, et al. High cholesterol level is essential for myelin membrane growth. Nat Neurosci. 2005;8(4):468–75.

Gonzalez GA, Hofer MP, Syed YA, Amaral AI, Rundle J, Rahman S, et al. Tamoxifen accelerates the repair of demyelinated lesions in the central nervous system. Sci Rep. 2016;6:31599.

Hubler Z, Allimuthu D, Bederman I, Elitt MS, Madhavan M, Allan KC, et al. Accumulation of 8,9-unsaturated sterols drives oligodendrocyte formation and remyelination. Nature. 2018;560(7718):372–6.

Saluja I, Granneman JG, Skoff RP. PPAR δ agonists stimulate oligodendrocyte differentiation in tissue culture. Glia. 2001;33:191–204.

Article  CAS  PubMed  Google Scholar 

Bernardo A, Bianchi D, Magnaghi V, Minghetti L. Peroxisome proliferator-activated receptor-γ agonists promote differentiation and antioxidant defenses of oligodendrocyte progenitor cells. J Neuropathol Exp Neurol. 2009;68(7):797–808.

Vinolo MAR, Rodrigues HG, Nachbar RT, Curi R. Regulation of inflammation by short chain fatty acids. Nutrients. 2011;3:858–76.

Mullin AP, Cui C, Wang Y, Wang J, Troy E, Caggiano AO, et al. rHIgM22 enhances remyelination in the brain of the cuprizone mouse model of demyelination. Neurobiol Dis. 2017;105:142–55.

Zorina Y, Stricker J, Caggiano AO, Button DC. Human IgM antibody rHIgM22 promotes phagocytic clearance of myelin debris by microglia. Sci Rep. 2018;8(1):9392.

Nastasijevic B, Wright BR, Smestad J, Warrington AE, Rodriguez M, Maher LJ. Remyelination induced by a DNA Aptamer in a mouse model of multiple sclerosis. PLoS One. 2012;7(6):e39595.

Bove RM, Green AJ. Remyelinating Pharmacotherapies in Multiple Sclerosis. Neurotherapeutics [Internet]. 2017;14:894–904. Available from: http://link.springer.com/https://doi.org/10.1007/s13311-017-0577-0

Salewski RP, Mitchell RA, Li L, Shen C, Milekovskaia M, Nagy A, et al. Transplantation of Induced Pluripotent Stem Cell-Derived Neural Stem Cells Mediate Functional Recovery Following Thoracic Spinal Cord Injury Through Remyelination of Axons. Stem Cells Transl Med. 2015;4(7):743–54.

Kawabata S, Takano M, Numasawa-Kuroiwa Y, Itakura G, Kobayashi Y, Nishiyama Y, et al. Grafted Human iPS Cell-Derived Oligodendrocyte Precursor Cells Contribute to Robust Remyelination of Demyelinated Axons after Spinal Cord Injury. Stem Cell Reports. 2016;6(1):1–8.

Morales Pantoja IE, Smith MD, Rajbhandari L, Cheng L, Gao Y, Mahairaki V, et al. IPSCs from people with MS can differentiate into oligodendrocytes in a homeostatic but not an inflammatory milieu. PLoS One. 2020;15(6):e0233980.

Piaton G, Aigrot M-S, Williams A, Moyon S, Tepavcevic V, Moutkine I, et al. Class 3 semaphorins influence oligodendrocyte precursor recruitment and remyelination in adult central nervous system. Brain [Internet]. 2011;134:1156–67. Available from: https://academic.oup.com/brain/article-lookup/doi/https://doi.org/10.1093/brain/awr022

Kotsiari A, Voss EV, Pul R, Skripuletz T, Ragancokova D, Trebst C, et al. Interferon-beta treatment normalises the inhibitory effect of serum from multiple sclerosis patients on oligodendrocyte progenitor proliferation. Neurosci Lett. 2010;485:107–11.

Article  CAS  PubMed  Google Scholar 

Mastronardi FG, Min W, Wang H, Winer S, Dosch M, Boggs JM, et al. Attenuation of Experimental Autoimmune Encephalomyelitis and Nonimmune Demyelination by IFN-β plus Vitamin B12: Treatment to Modify Notch-1/Sonic Hedgehog Balance. J Immunol. 2004;172:6418–26.

Article  CAS  PubMed  Google Scholar 

Heine S, Ebnet J, Maysami S, Stangel M. Effects of interferon-beta on oligodendroglial cells. J Neuroimmunol. 2006;177:173–80.

Article  CAS  PubMed  Google Scholar 

Fowler JH, McQueen J, Holland PR, Manso Y, Marangoni M, Scott F, et al. Dimethyl fumarate improves white matter function following severe hypoperfusion: Involvement of microglia/macrophages and inflammatory mediators. J Cereb Blood Flow Metab. 2018;38(8):1354–70.

Pars K, Gingele M, Kronenberg J, Prajeeth CK, Skripuletz T, Pul R, et al. Fumaric acids do not directly influence gene expression of neuroprotective factors in highly purified rodent astrocytes. Brain Sci. 2019;9(9):241.

Weber MS, Hohlfeld R, Zamvil SS. Mechanism of Action of Glatiramer Acetate in Treatment of Multiple Sclerosis. Neurotherapeutics. 2007;4:647–53.

Evangelidou M, Karamita M, Vamvakas S-S, Szymkowski DE, Probert L. Altered Expression of Oligodendrocyte and Neuronal Marker Genes Predicts the Clinical Onset of Autoimmune Encephalomyelitis and Indicates the Effectiveness of Multiple Sclerosis-Directed Therapeutics. J Immunol. 2014;192:4122–33.

Article  CAS  PubMed  Google Scholar 

From R, Eilam R, Bar-Lev DD, Levin-Zaidman S, Tsoory M, LoPresti P, et al. Oligodendrogenesis and myelinogenesis during postnatal development effect of glatiramer acetate. Glia. 2014;62:649–65.

Article  PubMed  Google Scholar 

Bieberich E. There is more to a lipid than just being a fat: Sphingolipid-Guided differentiation of oligodendroglial lineage from embryonic stem cells. Neurochem Res. 2011;36(9):1601–11.

Alme MN, Nystad AE, Bø L, Myhr KM, Vedeler CA, Wergeland S, et al. Fingolimod does not enhance cerebellar remyelination in the cuprizone model. J Neuroimmunol. 2015;285:180–6.

Mindur JE, Ito N, Dhib-Jalbut S, Ito K. Early Treatment with Anti-VLA-4 mAb Can Prevent the Infiltration and/or Development of Pathogenic CD11b+CD4+ T Cells in the CNS during Progressive EAE. PLoS ONE. 2014;9: e99068.

Article  PubMed  PubMed Central  Google Scholar 

Lassmann H, Van Horssen J, Mahad D. Progressive multiple sclerosis: Pathology and pathogenesis. Nat Rev Neurol. 2012;8(11):647–56.

Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain. 1997;120(3):393–9.

Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal Transection in the Lesions of Multiple Sclerosis. N Engl J Med. 1998;338:278–85.

Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol. 2015;15:545–58.

Article  CAS  PubMed  Google Scholar 

Klotz L, Eschborn M, Lindner M, Liebmann M, Herold M, Janoschka C, et al. Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects. Sci Transl Med. 2019;11(490):eaao5563.

Li R, Rezk A, Ghadiri M, Luessi F, Zipp F, Li H, et al. Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis. J Immun. 2017;98(2):691–8.

Oh J, O’Connor PW. Established disease-modifying treatments in relapsing-remitting multiple sclerosis. Curr Opin Neurol. 2015;28(3):220–9.

Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162–73.

Ontaneda D, Thompson AJ, Fox RJ, Cohen JA. Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function. The Lancet. 2017;389(10076):1357–66.

Heneka MT, Kummer MP, Latz E. Innate immune activation in neurodegenerative disease. Nat Rev Immunol. 2014;14:463–77.

Article  CAS  PubMed  Google Scholar 

Miron VE, Franklin RJM. Macrophages and CNS remyelination. J Neurochem. 2014;130:165–71.

Article  CAS  PubMed  Google Scholar 

Chu F, Shi M, Zheng C, Shen D, Zhu J, Zheng X, et al. The roles of macrophages and microglia in multiple sclerosis and experimental autoimmune encephalomyelitis. J Neuroimmunol. 2018;318:1–7.